Export of Pharmaceutical Product Capacity under Epidemic Situation

For Chinese pharmaceutical companies, this is not only a sniper war on epidemic prevention and control. But It’s also a decisive battle to defend their own supply chain status. Huahai Pharmaceutical (600521.SH) from Zhejiang said, “The company has gradually resumed work on February 10. And currently all eligible employees have returned to work.” The company is the world’s largest API and sartan API. The supplier was selected as the first batch of provincial key foreign trade enterprises in Zhejiang Province to return to work and give priority to the list. It is the only selected company in the province’s pharmaceutical industry.

After the outbreak, medical insurance and finance made every effort to protect against epidemics. Hospitals’ payback periods for pharmaceutical commercial enterprises were prolonged to varying degrees in most regions. In accordance with the 28th principle, pharmaceutical commercial enterprises focused on guaranteeing repayment by foreign and large domestic enterprises. Coupled with the help of various financial policies, the production capacity of Chinese companies has been rapidly increased. While the country has met the needs of its own pharmaceutical products, the country has already been able to start exporting, praise China and cheer for the world